Pharmafile Logo

10 Remapping the Market

November 14, 2014 |  

Does pharma’s global model need a shake up?

Digital has succeeded where armies, politics and religion have failed; taking over the world. Where once there was Alexander the Great, Augustus Caesar, Genghis Khan and Napoleon Bonaparte, we now have Mark Zuckerberg, Larry Page, Jeff Bezos and (until recently) Steve Jobs. We speak one language, adopt new behaviours, and follow the same brands. So what does this mean to pharma and its global approach to business?

The global invasion of Apple, Paypal, Instagram and others has conditioned what people have come to expect from digital experiences. They’ve set a standard that is recognised worldwide and moulded a uniformity in digital behaviours. Consider how intuitively a person can use an iPad, or the like, share and comment behaviours that are inherent in all social networks. Platforms may vary, but the means of interaction remain the same.

Line, Japan’s most popular social network , features a timeline and homepage akin to that of Facebook. 69% of internet use in Germany is via a computer, where as in Kenya usage swings dramatically towards mobile (98%). Yet in both, the average time an internet user spends online is around the 3 hour mark.

Furthermore, the digital global standard is extremely far reaching. The ‘unconnected’ global population is ever dwindling. India is experiencing 58% year-on-year growth of internet users amongst its rural communities, whilst mobile phones are a common commodity even to remote East African nomadic herders who live without regular access to electricity or running water. In such communities, digital healthcare support, however basic, is all the more valuable. It might be difficult and costly for a patient to reach the nearest healthcare professional, but if they can quickly and inexpensively seek medical advice online, or even via text or phone call, symptoms that might otherwise be ignored can be alleviated.

This content was provided by Havas Lynx

Documents for download:

Company Details

 Latest Content from  Havas Lynx 

Havas Lynx Group launches proprietary data product to drive meaningful change across pharma

Leading global healthcare communications agency, Havas Lynx Group, has launched its proprietary data platform, Point.1, to help pharmaceutical companies to gain a deeper understanding of healthcare professionals (HCPs) to drive...

Healing the Healers

Because if we do not heal the healers, who is going to heal us?

THE HIDDEN LIFESAVERS: overdose prevention campaign launches nationwide

The campaign encourages people who use drugs to do something remarkable – save a life

Andi Goes – the children’s book that helps detect early signs of dyslexia

Havas Lynx Group have launched a children’s book aimed at raising awareness and detecting early signs of dyslexia. Helping to make sure that parents have the support they need whilst...

Neurofibromatosis: a condition that’s hard to say, but even harder to live with

The Childhood Tumour Trust and Havas Lynx Group have launched a campaign to raise awareness and funds for people living with a rare genetic condition, neurofibromatosis 1 (NF1).

Havas Health & You Launches Behind the Mask, a Global Research Initiative to Document Health Experiences During the COVID-19 Pandemic and Beyond

Havas Health & You (HH&Y) have launched the details of a long-term global research project, Behind the Mask, a longitudinal, multi-armed study which focuses on documenting the ongoing evolution of...

Media Means Business

Creating meaningful media experiences in pharma

Havas Lynx Group elevates Jon Chapman and Paul Kinsella to CCOs

Havas Lynx Group announces the promotion of Jon Chapman and Paul Kinsella from Executive Creative Directors (ECD) to Chief Creative Officers (CCO) for Havas Lynx Group.